Drug resistance mechanism and treatment strategy for targeted therapy of melanoma

doi:10.3760/cma.j.issn.1673-422X.2018.07.013

Journal of International Oncology ›› 2018, Vol. 45 ›› Issue (7): 444-448.doi: 10.3760/cma.j.issn.1673-422X.2018.07.013

Drug resistance mechanism and treatment strategy for targeted therapy of melanoma

Jin Lan, Kang Xiaojing

Postgraduate School of Xinjiang Medical University; Department of Dermatology and Venereology, People′s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830001, China

Online:2018-07-08 Published:2018-07-31
Contact: Kang Xiaojing, Email: drkangxj666@163.com E-mail:drkangxj666@163.com
Supported by:
Natural Science Foundation of Xinjiang Uygur Autonomous Region of China (2016D01C101)

Abstract

Abstract: Drug resistance of targeted therapy gradually emerges in the treatment of melanoma. Currently known mechanisms of drug resistance include reactivation of mitogenactivated protein kinase (MAPK) pathway, activation of MAPK alternative pathway, effects of tumor microenvironment, and abnormal expression of microRNA. Through the combination of targeted drugs, immunological combination therapy and other strategies can delay the occurrence of drug resistance, thereby prolonging the survival of patients.

Key words: Melanoma, Drug resistance, neoplasm, Targeted therapy

Jin Lan, Kang Xiaojing. Drug resistance mechanism and treatment strategy for targeted therapy of melanoma[J]. Journal of International Oncology, 2018, 45(7): 444-448.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Huang Hui, Ding Jianghua. Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma [J]. Journal of International Oncology, 2023, 50(9): 569-573.
[5]	Wang Ting, Li Wenqian, Xie Youbang. Correlation between hypoxia and the oxygen sensing pathway in acute myeloid leukemia cells [J]. Journal of International Oncology, 2023, 50(8): 503-507.
[6]	Wu Minhang, Sun Wenzheng, Yu Qingzhuo, Guo Rong, Ye Hui, Du Ying, Qiu Jin, An Huazhang, Cao Lili. RNF43 inhibits PD-L1 expression via β-catenin in melanoma cells and promotes CD8⁺ T cell-mediated anti-tumor immune reaction [J]. Journal of International Oncology, 2023, 50(7): 407-412.
[7]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[8]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong. Progress of PARP inhibitors in targeted therapy of small cell lung cancer [J]. Journal of International Oncology, 2023, 50(6): 368-372.
[9]	Liu Bohan, Huang Junxing. Research progress of solute carriers related genes in malignant tumors [J]. Journal of International Oncology, 2023, 50(5): 280-284.
[10]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[11]	Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757.
[12]	Liu Shaoping, Luo Hanchuan, Lin Shuhan, Luo Jiahui. Current status and research progress of interventional and systemic therapy for advanced hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(12): 758-762.
[13]	Jiang Shan, Xu Ximing. Recent progresses of targeted therapy and immunotherapy of hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(11): 688-695.
[14]	Jiang Shan, Xu Yangtao, Liu Xin, Chen Wenliang, Xu Ximing. Predictive value of baseline peripheral blood inflammatory biomarkers for prognosis in patients with advanced hepatocellular carcinoma treated with immunotherapy combined with targeted therapy [J]. Journal of International Oncology, 2023, 50(10): 600-607.
[15]	Zhang Jingxian, Su Jianfei, Wei Xueqin, Yi Dan, Li Xiaojiang. Treatment status of non-small cell lung cancer with METexon14 skipping mutation [J]. Journal of International Oncology, 2023, 50(1): 37-41.

Drug resistance mechanism and treatment strategy for targeted therapy of melanoma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments